Vanguard Personalized Indexing Management LLC Has $4.71 Million Stock Position in Humana Inc. $HUM

Vanguard Personalized Indexing Management LLC lifted its position in Humana Inc. (NYSE:HUM) by 25.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,113 shares of the insurance provider’s stock after buying an additional 3,660 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Humana were worth $4,713,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Lorne Steinberg Wealth Management Inc. acquired a new position in Humana in the third quarter valued at about $208,000. AMF Tjanstepension AB lifted its holdings in shares of Humana by 24.4% during the 3rd quarter. AMF Tjanstepension AB now owns 91,901 shares of the insurance provider’s stock valued at $23,910,000 after purchasing an additional 17,999 shares in the last quarter. Sector Gamma AS grew its position in shares of Humana by 1.9% in the 3rd quarter. Sector Gamma AS now owns 23,942 shares of the insurance provider’s stock valued at $6,229,000 after purchasing an additional 442 shares during the period. Sagespring Wealth Partners LLC acquired a new position in shares of Humana in the 3rd quarter valued at approximately $201,000. Finally, Stoneridge Investment Partners LLC increased its stake in Humana by 58.5% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 6,565 shares of the insurance provider’s stock worth $1,708,000 after purchasing an additional 2,423 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $193.89 on Thursday. The stock has a market capitalization of $23.32 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.71 and a beta of 0.45. Humana Inc. has a 12 month low of $191.39 and a 12 month high of $315.35. The firm has a fifty day simple moving average of $257.61 and a 200 day simple moving average of $264.43. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a net margin of 1.02% and a return on equity of 12.86%. The firm had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. During the same period in the previous year, the business earned $4.16 EPS. The company’s revenue was up 11.1% compared to the same quarter last year. Research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Some market commentators frame the selloff as a buying opportunity given Humana’s scale in Medicare Advantage and recent outperformance vs. peers; this view argues the weakness may create a value entry point. Humana’s Health Scare Sinks Stock To 9-Year Low. Time To Buy?
• Neutral Sentiment: Upcoming catalyst: Humana will present fourth‑quarter and full‑year 2025 results on Feb. 6 — this report and guidance will be a key near‑term test of whether the company can offset payment pressure with expense control or membership gains. Humana to Present Fourth-Quarter and Full-Year 2025 Results on 6 February
• Neutral Sentiment: Valuation debate: commentators are split between calling HUM a discounted value play vs. a potential value trap if Medicare rate pressure persists — expect divergent analyst takes in the coming days. Is Humana Stock Now A Value Trap At $200?
• Negative Sentiment: Primary driver of the selloff: the CMS proposal to keep Medicare Advantage rates roughly flat for 2027 reduces expected revenue growth for carriers and increases uncertainty about 2026–27 margins; UnitedHealth led the rout and Humana was hit hard as a large MA operator. UnitedHealth Leads $80 Billion Insurer Rout on Bleak Medicare Advantage Proposal
• Negative Sentiment: Market reaction: Humana plunged ~21% on the Medicare payment update, hitting multi‑year lows and signaling accelerated downside risk as investors reprice MA exposure. Humana (HUM) Falls 21% on Medicare Payment Update
• Negative Sentiment: Analyst commentary: several outlets and analysts warn there’s “no quick fix” for the rate shock — if CMS finalizes low increases, Humana may face sustained margin pressure and slower earnings growth. UnitedHealth, Humana: CMS’ Rate Decision Has Crushed Stock, & There’s No Quick Fix
• Negative Sentiment: Structural/operational risks: reporting suggests tighter CMS rates could collide with expanding at‑home cardiac care and other cost-heavy initiatives, and there are localized provider/contract risks (e.g., potential partner terminations) that could further pressure membership or margins. Humana Faces Tight CMS Rates As At Home Cardiac Care Expands Queen’s May Cut Ties With This For-Profit Medicare Insurer

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. The Goldman Sachs Group cut their price target on shares of Humana from $235.00 to $215.00 and set a “sell” rating on the stock in a research note on Monday, November 24th. KeyCorp restated a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Zacks Research cut shares of Humana from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Wells Fargo & Company lowered shares of Humana from an “overweight” rating to a “cautious” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley reiterated an “underperform” rating on shares of Humana in a report on Thursday, December 18th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $293.37.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.